Drugs / Angiotensin II
Angiotensin II
also known as
Giapreza · Ang II · ATII · LJPC-501 · 5-l-isoleucineangiotensin ii · AII · Angiotensin ii (human type) · ANGIOTENSIN II ACETATE · +8 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Giapreza | — | 2019-08-23 | europa.eu ↗ |
| Approved | US (FDA) | GIAPREZA | — | 2017-12-21 | fda.gov ↗ |
Trials 31
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06157580 | Dec 2023 → Oct 2024 | preeclampsia | Anna Stanhewicz, PhD | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT01906307 | Mar 2014 → Nov 2015 | hepatorenal syndrome | La Jolla Pharmaceutical Company | Terminated | No outcome recorded |
| Phase 1 | NCT01426529 | Oct 2010 → Oct 2026 expected | hypertensive disorder | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00962949 | Apr 2009 → Dec 2012 | postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2030 expected | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | D. Walter Wray | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07312292 | Jan 2026 → May 2027 expected | liver cancer | Niek Wijnen | Recruiting | No outcome recorded |
| Phase 2 | NCT04048707 | Jul 2021 → Jun 2023 | acute kidney injury, cirrhosis of liver, hepatorenal syndrome | University of California, Los Angeles | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03623529 | Aug 2018 → Mar 2023 | infectious disease with sepsis | La Jolla Pharmaceutical Company | Unknown | No outcome recorded |
| Phase 2 | NCT03431077 | Feb → Apr 2018 | infectious disease with sepsis | La Jolla Pharmaceutical Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04901169 | Jun 2022 → Mar 2026 overdue | vascular disorder | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 35 trials · 1 met primary | ||||||
| Phase 3 | NCT06615102 | Mar 2025 → Jan 2027 expected | vascular disorder | University of Münster | Recruiting | No outcome recorded |
| Phase 3 | NCT06351150 | Jul 2024 → Jun 2027 expected | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05199493 | Dec 2021 → Dec 2022 | cardiac valvular defect, vascular disorder | University of Münster | Completed | No outcome recorded |
| Phase 3 | NCT03302650 | Apr → Aug 2019 | infectious disease with sepsis | Cairo University | Suspended | No outcome recorded |
| Phase 3 | NCT02338843 | Mar 2015 → Dec 2016 | infectious disease with sepsis | La Jolla Pharmaceutical Company | Completed | Met primary |
| Phase 412 trials | ||||||
| Phase 4 | NCT06746753 | Nov 2026 → Sep 2028 expected | infectious disease with sepsis | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07671365 | Jul 2026 → Jul 2029 expected | cardiogenic shock, vascular disorder | Methodist Healthcare System of San Antonio | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07212686 | Sep 2025 → Jun 2030 expected | — | Todd Sweberg | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06487585 | May 2025 → Jan 2026 overdue | arterial disorder | University of Maryland St. Joseph Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06693726 | Apr 2025 → Dec 2026 expected | infectious disease with sepsis | Brett A Faine | Recruiting | No outcome recorded |
| Phase 4 | NCT06122987 | Dec 2023 → Dec 2024 | infectious disease with sepsis | Kingman Regional Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05824767 | Apr 2023 → Mar 2025 | infectious disease with sepsis | University of New Mexico | Completed | No outcome recorded |
| Phase 4 | NCT04592744 | Apr 2022 → Dec 2026 expected | acute kidney injury, chronic liver failure, cirrhosis of liver | University of California, Los Angeles | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05193370 | Jan → Nov 2022 | infectious disease with sepsis | University of New Mexico | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04558359 | Oct 2020 → Jul 2023 | acute kidney injury, infectious disease with sepsis | Alexander Flannery | Completed | No outcome recorded |
| Phase 4 | NCT04529005 | Aug 2020 → Aug 2021 | hypotensive disorder | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT03733145 | Oct 2019 → Mar 2023 | hypertensive disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06234592 | Jan 2024 → Jan 2026 overdue | acute kidney injury, infectious disease with sepsis | King's College Hospital NHS Trust | Recruiting | No outcome recorded |
| — | NCT00901745 | May 2009 → Apr 2010 | heart disorder, isoproterenol-mediated vasodilatation | University of Edinburgh | Completed | No outcome recorded |
| — | NCT01024543 | Oct 2006 → Nov 2009 | — | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03245528 | — | high output heart failure, infectious disease with sepsis | La Jolla Pharmaceutical Company | Approved for marketing | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT07568275 Comparator | Nov 2024 → Jan 2028 expected | acute kidney injury, cirrhosis of liver, infectious disease with sepsis | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01393782 Comparator | Jul 2011 → Jan 2014 | infectious disease with sepsis | George Washington University | Completed | No outcome recorded |
| Phase 2 | NCT00711789 Comparator | Feb 2010 → Feb 2013 | acute kidney injury, infectious disease with sepsis | Austin Health | Unknown | No outcome recorded |
| Phase 4 | NCT04904562 Comparator | Jun 2022 → May 2024 | — | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01502787 Comparator | Apr 2009 → Jun 2013 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT01702688 Background | Jul 2012 → ? | essential hypertension | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| — | NCT01049646 Comparator | Jan → Apr 2010 | — | University of Edinburgh | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 国内首家！正大天晴血管紧张素Ⅱ注射液（TQG3902）取得临床批件 cttq.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 国内首家！正大天晴血管紧张素Ⅱ注射液（TQG3902）取得临床批件 cttq.com ↗ |
| 2023-03-16 | Paion UK Ltd. | PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS paion.com ↗ |
| 2021-07-16 | Paion UK Ltd. | PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY paion.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | angiotensin II | “angiotensin II” NCT03245528 ↗ |
| Known as | 5-l-isoleucineangiotensin ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | AII | “Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study” NCT01393782 ↗ |
| Known as | Ang II | “We have previously found that patients with POTS have increases in plasma angiotensin II (Ang II) that are twice as high as healthy subjects despite normal blood pressures (BPs).” PMID 22247480 ↗ Jan 20122“Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume.” NCT01702688 ↗ “such as angiotensin II (Giapreza - Ang II) in perioperative kidney transplant patients” NCT04529005 ↗ |
| Known as | Angiotensin ii (human type) | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | ANGIOTENSIN II ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | Angiotensin ii acetate human | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | Angiotensin ii human | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | Angiotensin ii triacetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | Angiotensina ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | Angiotensine ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | Asp-arg-val-tyr-ile-his-pro-phe | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | ATII | “Following informed consent, patients will receive intravenous angiotensin II (AT-II) infusion for blood pressure support.” NCT06693726 ↗2“Biomarker-guided Implementation of Angiotensin-II (AT-II) to Reduce the Occurrence of Kidney Damage After Cardiac Surgery” NCT05199493 ↗ “Angiotensin II (ATII) may prove useful in patients who remain hypotensive despite catecholamine and vasopressin therapy.” PMID 25286986 ↗ Oct 2014 |
| Known as | Delivert | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | Giapreza | “Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS).” NCT05824767 ↗4“such as angiotensin II (Giapreza - Ang II) in perioperative kidney transplant patients” NCT04529005 ↗ “Drug: Angiotensin II (Giapreza®)” NCT07312292 ↗ “Angiotensin II (Giapreza®)” NCT07671365 ↗ |
| Known as | Human angiotensin ii acetate salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL408403 ↗ |
| Known as | LJPC-501 | “Drug: LJPC-501 (angiotensin II)” NCT03623529 ↗ |
| Action | Activate | “Type-1 angiotensin II receptor agonist” CHEMBL408403 ↗ |
| Modality | Peptide | “Angiotensin II is a peptide hormone naturally produced by the body” NCT03431077 ↗ |
| Route | Other | “Angiotensin II will be given by continuous infusion” NCT00711789 ↗ |
| Target | AGTR1 | “Type-1 angiotensin II receptor agonist” CHEMBL408403 ↗ |